Cvrx, Inc. Stock Price, News & Analysis

CVRx plans to release its first quarter 2023 financial and operational results on April 27, 2023, after market close. The company will host a conference call at 5:00 p.m. Eastern Time that day to discuss these results. Investors can access a live webcast on the investor relations page of CVRx's website. CVRx focuses on developing the Barostim™, a groundbreaking implantable neuromodulation device for cardiovascular diseases, which has received FDA approval and Breakthrough Device designation. Barostim aims to alleviate heart failure symptoms by delivering electrical pulses to baroreceptors in the carotid artery, restoring balance to the autonomic nervous system.

CVRx, a medical device company, announced preliminary results from the BeAT-HF trial at the THT conference on March 21, 2023. Conducted on the Barostim device, these results showed a 97% rate of major adverse events, with significant long-term improvements in patient outcomes. The device led to a 34% reduction in all-cause mortality compared to control, and a win ratio of 1.26 favoring Barostim. The data supports Barostim as a safe and effective therapy for heart failure. CVRx plans to submit this data to the FDA for expanded labeling and anticipates publication of full results in peer-reviewed journals.

CVRx, a medical device company specializing in neuromodulation for cardiovascular diseases, announced plans to present preliminary results from the BeAT-HF trial at the Technology and Heart Failure Therapeutics (THT) conference on March 21, 2023. Dr. Michael Zile from MUSC will present these results. The company will also sponsor a symposium titled 'Baroreflex Activation Therapy in HFrEF: New Insights from the BeAT-HF Study' during the conference. Subsequently, CVRx will hold an investor conference call at 4:30 pm ET to discuss the results. Barostim™, their FDA-approved device, aims to alleviate heart failure symptoms through autonomic balance restoration.

CVRx announced preliminary results from the BeAT-HF trial, assessing the Barostim device for heart failure treatment. The trial included 323 patients, comparing Barostim + medical therapy to medical therapy alone. While the primary endpoint was not statistically significant, additional analyses indicated potential benefits, including improved all-cause survival and quality of life. The safety profile of Barostim remained robust over 24 months. CVRx intends to submit these findings to the FDA for expanded labeling. The results will be discussed in a conference call on February 21, 2023, and presented at the THT Conference on March 21, 2023.